Form 8-K - Current report:
SEC Accession No. 0001178913-25-002390
Filing Date
2025-07-16
Accepted
2025-07-16 08:55:44
Documents
15
Period of Report
2025-07-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2533447.htm   iXBRL 8-K 49263
2 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 15013
7 image00002.jpg GRAPHIC 322344
  Complete submission text file 0001178913-25-002390.txt   687546

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA slxn-20250716.xsd EX-101.SCH 4625
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20250716_def.xml EX-101.DEF 18268
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20250716_lab.xml EX-101.LAB 27759
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20250716_pre.xml EX-101.PRE 20510
18 EXTRACTED XBRL INSTANCE DOCUMENT zk2533447_htm.xml XML 6557
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42253 | Film No.: 251126226
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)